Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 18;7(8):270.
doi: 10.3390/microorganisms7080270.

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Despoina Koulenti  1   2 , Elena Xu  1 , Isaac Yin Sum Mok  1 , Andrew Song  1 , Drosos E Karageorgopoulos  3 , Apostolos Armaganidis  2 , Jeffrey Lipman  1   4   5 , Sotirios Tsiodras  3
Affiliations
Review

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Despoina Koulenti et al. Microorganisms. .

Abstract

Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel antibiotics effective against Gram-positive bacteria has been approved. This review will discuss the current evidence for novel branded antibiotics that are highly effective in the treatment of multidrug-resistant infections by Gram-positive pathogens, namely ceftobiprole, ceftaroline, telavancin, oritavancin, dalbavancin, tedizolid, besifloxacin, delafloxacin, ozenoxacin, and omadacycline. The mechanism of action, pharmacokinetics, microbiological spectrum, efficacy and safety profile will be concisely presented. As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future.

Keywords: and omadacycline; besifloxacin; ceftaroline; ceftobiprole; dalbavancin; delafloxacin; gram-positive pathogens; multidrug-resistance; novel antibiotics; oritavancin; ozenoxacin; tedizolid; telavancin.

PubMed Disclaimer

Conflict of interest statement

Author J.L. reports: Advisory Board with Bayer and MSD and honorarium for lectures from Pfizer and MSD. All other authors (DK, EX, AS, IYSM, DEK, AA and ST) declare no competing interests.

References

    1. Li B., Webster T.J. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J. Orthop. Res. 2018;36:22–32. - PMC - PubMed
    1. O’Neill J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist. 2014;20:1–16.
    1. David M.Z., Dryden M., Gottlieb T., Tattevin P., Gould I.M. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: The shock of the new. Int. J. Antimicrob. Agents. 2017;50:303–307. - PubMed
    1. Magiorakos A.P., Srinivasan A., Carey R., Carmeli Y., Falagas M., Giske C., Harbarth S., Hindler J., Kahlmeter G., Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. - PubMed
    1. Khameneh B., Diab R., Ghazvini K., Bazzaz B.S.F. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb. Pathog. 2016;95:32–42. doi: 10.1016/j.micpath.2016.02.009. - DOI - PubMed

LinkOut - more resources